Key Alert: TapImmune worth keeping an eye on Print E-mail
By M.E.Garza   
Wednesday, 08 September 2010 12:51

As we told our subscribers yesterday, TapImmune Inc. (OTCBB:TPIV) is starting to pick some momentum as a bottom-up play which features innovative therapeutics and vaccines in the areas of oncology and infectious disease.  Their TAP technology deals directly with the cellular arm of the immune system is critical in protecting us against malignant cells that develop into deadly, metastatic cancers.

Shares of this biotechnology company which aims to treat and eradication cancer as well as to prevent infectious disease were up sharply yesterday on rumors that the company would be making some critical changes as they evolve into the next stage of their preclinical  and clinical programs and these developments could turn into the next leg-up for the stock. Especially if the company's TAP platform proves to be as promising as ABC, BusinessWeek and Popular Mechanics have made it sound when they covered it.

The stock traded as high as $1.56 during the last 52 weeks, but it finds itself down to mere pennies despite the fact they have announced announced collaborative agreements with the Mayo Clinic in Breast Cancer and Smallpox recently.

The rumors we were hearing yesterday were confirmed today when the company announced the following appointment to its Board of Directors and Advisory Team:

Lynn M. DePippo has been appointed to the company's Board of Directors. She is the Founder and Managing Partner, Sherbrook Capital Management. Her pPrevious appointments include Portfolio Manager Small Cap Equities at Citibank, Senior Investment Analyst at The Kaufmann Fund, NY, and Healthcare Services Analyst at Kidder Peabody and Company, N.Y. TapImmune will be looking for DePippo's experience in the financing and growth of healthcare companies as they enter the next phase of the growth.

TapImmune also announced the formation of its Advisory Team:

Dr. Martin "Mac" Cheever, Director of Solid Tumor Research Program, Fred Hutchinson Cancer Research Center, Seattle.  Cheever is internationally renowned for his contributions to cancer immunotherapy and for moving "cutting edge" technologies from the lab into the clinic. He co-founded vaccine company Corixa, Seattle, WA and has been involved on the clinical development of breast cancer vaccines. He is a consultant to the National Cancer Institute on priorities for immunotherapy.

Dr. Roopa Srinivasan, has extensive experience in the preclinical development of biological therapeutics including antibodies, vaccines and gene therapy products. She was formerly Head and Program Leader, Tumor Immunology at CancerVax Corporation and Associate Director, Preclinical Development at Pain Therapeutics. She has a background in the cellular immunology of infectious disease and was a Research Associate, Department of Immunology, Sloan-Kettering Cancer Center, NY.

Mark A. Reddish, has broad experience in preclinical and clinical development and product manufacturing. He was formerly Vice President, Product Development and Principal Investigator Biodefense at ID Biomedical, Bothell, WA and was Senior Director for R&D at Biomira Inc, Edmonton, Alberta, with responsibility for the preclinical development of their therapeutic cancer vaccine program. 

Dr. Glynn Wilson, the CEO of TapImmune told BioMedReports that the announcements are a critical step in the company's development.

“The appointment of these renowned individuals to our Board and Advisory Team is a significant step in the building of a world-class group that can advance our technology platform and clinical programs," said Dr. Wilson.  "Moreover, it provides endorsement of the strength of our technology and corporate direction. This team will provide immediate support for the exciting partnerships for the treatment of cancer and infectious disease that we have announced over the past few months including two collaborations with the Mayo Clinic and our relationship with Aeras Global TB Vaccine Foundation.  These partnerships provide TapImmune with a unique and strong product pipeline addressing unmet clinical needs in multi-billion dollar markets”.

From a fundamental analysis perspective, shares may easily continue to rise form these levels if the company starts to push its technology through the regulatory process with the FDA- as we are hearing they are prepared to do in the weeks and months ahead. The company has far fewer shares outstanding than most companies that trade at these levels, so prices can rise, as they did during yesterday's session rather quickly.

From a technical analysis perspective, the stock appears to have bottomed out and is now starting to pick up more momentum and visibility.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter